| Literature DB >> 31992406 |
Eric A Mann1, Srinivas Nandkumar1, Nancy Addy2, B Gail Demko3, Neil S Freedman4, M Boyd Gillespie5, William Headapohl6, Douglas B Kirsch7, Barbara A Phillips8, Ilene M Rosen9, Logan D Schneider10, Carl J Stepnowsky6, Kathleen L Yaremchuk11, Malvina B Eydelman1.
Abstract
None: In recent years, sleep-disordered breathing (SDB) has been recognized as a prevalent but under-diagnosed condition in adults and has prompted the need for new and better diagnostic and therapeutic options. To facilitate the development and availability of innovative, safe and effective SDB medical device technologies for patients in the United States, the US Food and Drug Administration collaborated with six SDB-related professional societies and a consumer advocacy organization to convene a public workshop focused on clinical investigations of SDB devices. Sleep medicine experts discussed appropriate definitions of terms used in the diagnosis and treatment of SDB, the use of home sleep testing versus polysomnography, clinical trial design issues in studying SDB devices, and current and future trends in digital health technologies for diagnosis and monitoring SDB. The panel's breadth of clinical expertise and experience across medical specialties provided useful and important insights regarding clinical trial designs for SDB devices.Entities:
Keywords: clinical trial; polysomnography; sleep apnea syndromes
Mesh:
Year: 2020 PMID: 31992406 PMCID: PMC7075096 DOI: 10.5664/jcsm.8226
Source DB: PubMed Journal: J Clin Sleep Med ISSN: 1550-9389 Impact factor: 4.062